ArticleBlood cancer journal2026

Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort.

Hossam M Ali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.